Benzodiazepines is a class of psychoactive drugs used for the treatment of anxiety, panic, insomnia, and seizures. Benzodiazepines can also be used for sedation prior to surgery or diagnostic procedures, general anesthesia, alcohol withdrawal, drug-associated agitation, muscle relaxation, depression, nausea, and vomiting. The effect of gamma-aminobutyric acid (GABA), a neurotransmitter, is enhanced by benzodiazepine drugs, which reduce the activity of neurons that cause anxiety and stress. The market for benzodiazepine drugs is anticipated to expand during the forecast period, owing to increase in the prevalence of insomnia, anxiety, seizures and panic disorders.
The benzodiazepine drugs market can be segmented on the basis of product type, application type, time of action type, and region. Based on product type, the benzodiazepine drugs market can be segmented into alprazolam, clorazepate, chlordiazepoxide, estazolam, diazepam, flurazepam, estazolam, oxazepam, loprazolam, triazolam, temazepam, and others. The alprazolam segment accounted for a major market share of the benzodiazepine drugs market in 2016, as alprazolam is one of the most prescribed drugs in the U.S. and it has received the FDA approval for the treatment of panic disorders. Rise in the prevalence of panic disorders in developing as well as developed countries and inclination of people toward preventive health care measures are factors anticipated to drive the alprazolam segment during the forecast period. Moreover, the others segment is estimated to expand at a significant CAGR during the forecast period, due to rising prevalence of other stress-related disorders among the people of developed as well as developing countries.
Based on application type, the benzodiazepine drugs market can be divided into seizures, agitation, insomnia, anxiety, alcohol withdrawal symptoms, muscle spasm symptoms, anesthesia supplements, and others. The anxiety segment holds the leading market share owing to high prevalence of stress-related disorders globally during the forecast period. In developed economies such as Canada, the U.S., Germany, France, Italy, and the U.K.; there exist high levels of stress associated with work or personal relationships, societal factors, genetic aspects, and environmental factors. These fuel the market for benzodiazepines drugs. Moreover, the others segment is expected to lead the market in terms of revenue during the forecast period.
Based on time of action, the benzodiazepine drugs market can be segmented into short-acting benzodiazepines and long-acting benzodiazepines. The short-acting benzodiazepines segment holds a major market share, owing to their lower hangover effect as compared to long-acting benzodiazepines. However, the long-acting benzodiazepines segment is anticipated to expand in the next few years, due to advancements in research and development in developed as well as developing countries.
Geographically, the global benzodiazepine drugs market has been segmented into five major regions viz. Europe, North America, Asia Pacific, Latin America, and Middle East & Africa. North America held a leading market share in terms of revenue in 2016, as major players in developed countries in the region have received FDA approvals for their benzodiazepines drugs. Rise in the prevalence of stress-related disorders and anesthesia requirements have increased the government participation in prevention and control of these disorders. This factor is likely to boost the market in North America during the forecast period. Europe is the second-largest market for benzodiazepine drugs. However, the market in Asia Pacific is expected to witness high growth during the forecast period, which is attributable to rising concerns about the prevention of stress-related disorders in highly populated countries in the region such as China and India.
Major players operating in the global benzodiazepine drugs market include Johnson & Johnson, Eli Lilly and Company, AstraZeneca plc, GlaxoSmithKline plc, Forrest Laboratories, Inc. (Alllergan), H. Lundbeck A/S, Pfizer, Inc. Merck & Co., Inc., and Sanofi S.A.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.